The FDA has pushed back the deadline for banning electric shock devices used in mental health treatment [1].
This delay extends the availability of controversial tools used in psychiatric care, potentially impacting patient safety and the regulatory timeline for mental health interventions in the U.S.
The agency moved the deadline, according to reports. The decision follows a period of scrutiny regarding the safety and efficacy of these devices in clinical settings [1]. Internal communications reviewed by STAT indicate that the agency wants additional time to assess potential risks associated with the technology [2].
Critics of the devices have long argued that such interventions can be harmful or inhumane. However, the FDA is now opting for a longer review period to ensure the regulatory framework is comprehensive before the ban takes full effect [1].
"The FDA is taking a more cautious approach," said one source familiar with the situation [3].
The shift in timing suggests a tension between the urgency of banning the devices and the need for a legally and scientifically sound regulatory process. By extending the window, the FDA can further analyze the impact of the ban on current treatment protocols, and the availability of alternatives for patients [1].
“"The FDA is taking a more cautious approach,"”
The delay indicates that the FDA is prioritizing a risk-assessment phase over an immediate ban. This move provides a temporary reprieve for facilities currently using these devices but may prolong the use of controversial treatments while the agency seeks to avoid regulatory gaps or legal challenges.
